This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Finance & Accounting, Life Sciences

Pharma/Biotech GTN Summit Benchmarking Report 2021

Posted by on 01 July 2021
Share this article

At the Pharma/Biotech GTN Summit 2021, over 200 attendees were polled on a range of key questions  related to GTN best practices. The results form the 2021 benchmarking report - explore all the data by downloading the PDF using the Download Now button above.

Key Takeaways

  • 69% say that accuracy is their top concern related to the current gross-to-net forecasting auditability
  • 42% say that accessing data through disparate sources is the risk factor that causes the most operational strain on gross-to-net estimation
  • The bottom-up method is the prevailing method used for forecasting GTN for pre-commercial (62%), early-stage revenue (77%) and mature (61%) companies
  • 54% reset returns rate quarterly
  • 70% plan 1 year out for their future scenario planning for Medicaid and other policy issues
Share this article